Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day

Maturitas

Volumn 50, Issue 3, 2005, Pages 222-230

  Landgren, M B ^a   Helmond, F A ^b   Engelen, S ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Organon Pharmaceuticals USA Inc   (United States)

Author keywords

Climacteric symptoms; Dose response; Hot flushes; Sweats; Tibolone; Vaginal bleeding

Indexed keywords

TIBOLONE;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG POTENCY; EDEMA; FEMALE; HEADACHE; HOT FLUSH; HUMAN; INCIDENCE; LEG EDEMA; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; MIGRAINE; PERIPHERAL EDEMA; SIDE EFFECT; SPOTTING; STATISTICAL SIGNIFICANCE; SWEAT; VAGINA BLEEDING; VAGINA DISCHARGE; WEIGHT GAIN;

EID: 13944279222     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.06.001     Document Type: Article

References (13)

1. Kloosterboer H.J. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 76:2001;231-238
2. Modelska K., Cummings S. Clinical review 140. Tibolone for postmenopausal women: systematic review of randomised trials. J Clin Endocrinol Metab. 87(1):2002;16-23
3. Bjarnason N.H., Bjarnason K., Haarbo J., Rosenquist C., Christiansen C. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab. 81:1996;2419-2422
4. Berning B., Kuijk C., van J.W., Coelingh Bennink H.J.T., Kicovic P.M., Fauser B.C.J.M. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone. 19:1996;395-399
5. Gallagher J.C., Baylink D.J., Freeman R., McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose finding studies. J Clin Endocinol Metab. 86:2001;4717-4726
6. Lindsay R., Hart D.M., Kraszweski A. A prospective, double-blind trial of sythetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. BMJ. 280:1980;1207-1209
7. Landgren M.B., Coelingh Bennink H.J.T., Helmond F.A., Engelen S. Dose-response analysis of effect of tibolone on climacteric symptoms. BJOG. 109:2002;1109-1114
8. Archer D.F., Picar J.H., Bottiglioni F. Menopause Study Group Leeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol. 83:1994;686-692
9. Hammar M., Christau S., Nathorst-Böös J., Rud T., Garre K. A double-blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol. 105:1998;904-911
10. Dören M., Rübig A., Coelingh Bennink H.J.T., Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate repolacement therapy. Menopause. 6:1999;299-306
11. De Gooyer M.E., Deckers G.H., Schoonen W.G.E.J., Verheul H.A.M., Kloosterboer H.J. Receptor profiling and endocrine interactions of tibolone. Steroids. 68:2003;21-30
12. Timmer C.J., Verheul H.A.M., Doorstam D.P. Pharmacokinetics of tibolone in early and late menopausal women. Br J Clin Pharmcol. 54:2002;101-106
13. Huber J., Palacios S., Berglund L., et al. The effect of tibolone compared with conjugated equine oestrogens coninuously combined with medroxyprogestorne acetate on bleeding rates, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaecol. 109:2002;886-893